Multikine® (Leukocyte Interleukin, Injection), or Multikine* -- an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and cervical dysplasia in human immunodeficiency virus, or HIV, and human papillomavirus, or HPV co-infected patients.
* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.
L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS** -- has two investigational therapies, CEL-4000, a vaccine product candidate under development for the potential treatment of rheumatoid arthritis and LEAPS-H1N1-DC, a product candidate under development for the potential treatment of pandemic influenza in hospitalized patients.
** LEAPS is the name of CEL-SCI for this investigational platform technology. No LEAPS product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, pre-clinical-trials data involving these investigational products.